2342 — TransGenic Cashflow Statement
0.000.00%
Last trade - 00:00- ¥3bn
- ¥3bn
- ¥13bn
Annual cashflow statement for TransGenic, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -250 | 695 | 2,768 | -332 | 43.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 337 | 158 | -680 | 166 | 78.9 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -339 | 264 | -526 | -1,448 | -665 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -21 | 1,369 | 1,789 | -1,430 | -392 |
| Capital Expenditures | -257 | -146 | -532 | -306 | -266 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -61.9 | 194 | 1,514 | 90.3 | -15.3 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -319 | 48.4 | 982 | -216 | -281 |
| Financing Cash Flow Items | -61.3 | -146 | -73.9 | -16.1 | -16.1 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 667 | 10 | -1,183 | 485 | -343 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 326 | 1,427 | 1,588 | -1,159 | -993 |